Last updated on August 2020

Study to Assess the Efficacy Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Eye Disease | Eye Disorders/Infections | Eye Disorders/Infections (Pediatric) | Ocular Hypertension | Open Angle Glaucoma | Glaucoma | EYE DISORDER | Dry Eye Disease | Pigmentary glaucoma | Primary Open Angle Glaucoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Key Inclusion Criteria:

  • Diagnosis of OAG or OHT in each eye (OAG in one eye and OHT in the fellow eye is acceptable)
  • Must be receiving treatment with a stable regimen of topical prostaglandin eyedrop for a minimum of 2 weeks prior to the Screening Visit; may be taking one additional IOP lowering eyedrop
  • IOP of 18 mmHg and 27 mmHg in one eye at Screening visit
  • Following 4 week washout period, IOP 24 mmHg and < 36 mmHg at 08:00 hour and IOP 22 mmHg and < 36 mmHg in both eyes at 10:00, 12:00 and 16:00 hours.

Key Exclusion Criteria:

  • Clinically significant ocular disease which might interfere with interpretation of the study efficacy endpoints or with safety assessments
  • Pseudoexfoliation or pigment dispersion component glaucoma
  • History of angle closure glaucoma, or narrow angles or with evidence of peripheral anterior synechiae (PAS) 180 degrees by gonioscopy within 6 months prior to Screening
  • Intraocular pressure 36 mmHg
  • Cup/disc ratio of > 0.8 in either eye
  • Severe visual field defect or significant defect (sensitivity of 10dB) within 10 degrees of fixation in either eye

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.